Entasis Therapeutics Holdings Inc. (ETTX)
Stock Price:
$2.92 USD
-0.03 (-1.02%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
42.67M |
| Revenue (ttm) |
7.00M |
| Net Income (ttm) |
-46.18M |
| Shares Out |
27.29M |
| EPS (ttm) |
-3.50 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$2.92 |
| Previous Close |
$2.95 |
| Change ($) |
-0.03 |
| Change (%) |
-1.02% |
| Day's Open |
2.95 |
| Day's Range |
2.84 - 3.05 |
| Day's Volume |
243,889 |
| 52-Week Range |
1.75 - 9.25 |
More Stats
| Market Cap |
42.67M |
| Enterprise Value |
16.38M |
| Earnings Date (est) |
Aug 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
27.29M |
| Float |
3.89M |
| EPS (basic) |
-3.5 |
| EPS (diluted) |
-3.50 |
| FCF / Share |
-3.60 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
24,124 |
| Short Ratio |
0.41 |
| Short % of Float |
0.12% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
6.10 |
| PB Ratio |
2.91 |
| Revenue |
7.00M |
| Operating Income |
-48.15M |
| Net Income |
-46.18M |
| Free Cash Flow |
-47.78M |
| Net Cash |
26.29M |
| Net Cash / Share |
1.80 |
| Gross Margin |
100.00% |
| Operating Margin |
-687.83% |
| Profit Margin |
-659.60% |
| FCF Margin |
-682.57% |
| ROA |
-51.92% |
| ROE |
-93.97% |
| ROIC |
-130.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$6.25*
(114.04% upside)
Low
5.00
Current: 2.92
High
8.00
Target: 6.25
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 7.00 | 5.00 | - | - |
| Revenue Growth | 40% | - | - | - |
| Gross Profit | 7.00 | 5.00 | - | - |
| Operating Income | -46.94 | -38.21 | -31.34 | -19.10 |
| Net Income | -43.85 | -42.09 | -29.92 | -19.10 |
| Shares Outstanding | 13.16 | 3.42 | - | 0.10 |
| Earnings Per Share | -3.33 | -12.31 | -13,795.76 | -190,950.00 |
| Operating Cash Flow | -44.74 | -35.82 | -27.16 | -15.95 |
| Capital Expenditures | -0.11 | -0.37 | -0.29 | -0.14 |
| Free Cash Flow | -44.85 | -36.19 | -27.45 | -16.09 |
| Cash & Equivalents | 41.00 | 85.09 | 55.10 | 26.26 |
| Total Debt | 1.32 | - | - | - |
| Net Cash / Debt | 39.68 | 85.09 | 55.10 | 26.26 |
| Assets | 51.03 | 89.27 | 58.79 | 27.07 |
| Liabilities | 8.88 | 6.39 | 9.87 | 5.00 |
| Book Value | 42.16 | 82.88 | -55.79 | -26.34 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Entasis Therapeutics Holdings Inc. |
| Country |
United States |
| Employees |
48 |
| CEO |
Manoussos Perros |
Stock Information
| Ticker Symbol |
ETTX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ETTX |
| IPO Date |
September 26, 2018 |
Description
Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. It is involved in developing Sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that has completed Phase II clinical trial for the treatment of multi-drug resistant Acinetobacter infections; Zoliflodacin, a novel orally administered molecule that has completed Phase II clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant Gram-negative infections. The company has collaboration agreements with Zai Lab (Shanghai) Co., Ltd. for developing SUL-DUR. Entasis Therapeutics Holdings Inc. was incorporated in 2018 and is based in Waltham, Massachusetts.